Comparative analysis of IDegLira versus insulin glargine in short-term intensive therapy for overweight or obese patients with type 2 diabetes mellitus.

Sun Y, Li X, Xu L

Endocrine13 Jul 2026

PMID42439957DOI10.1007/s12020-026-04699-0PepBankPUB-42439957

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In severely hyperglycemic overweight or obese patients with T2D during seven-day intensive therapy, degludec/liraglutide plus aspart showed more high-quality glycemic control (65.1% versus 36.5%; P = 0.001) than glargine plus aspart.
In plain wordsIn overweight/obese patients with T2D, degludec/liraglutide plus aspart increased high-quality glycemic control versus glargine plus aspart.
Peptide
Liraglutide
Outcome
IncreaseHigh-quality glycemic control
Study
n: not reported in source
Comparator
Insulin glargine plus insulin aspart
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Measurements
High-quality glycemic control
65.1%
degludec/liraglutide plus aspart; P = 0.001
High-quality glycemic control
36.5%
glargine plus aspart; P = 0.001
Source sentences
Summary
The IDegLira group required less insulin (37.95 vs. 41.59 U/d, P = 0.03), achieved glycemic targets faster (3.1 vs. 5.0 days, P < 0.001), and had a higher rate of high-quality glycemic control (65.1% vs. 36.5%, P = 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
To compare the efficacy of insulin degludec/liraglutide (IDegLira) versus insulin glargine, both combined with insulin aspart, for short-term intensive glycemic control in overweight or obese patients with type 2 diabetes mellitus (T2DM).
Summary · context
In this randomized study, severely hyperglycemic overweight or obese patients with T2DM received 7-day intensive therapy with either IDegLira plus insulin aspart or insulin glargine plus insulin aspart.
Summary · context
The primary endpoint was the proportion of patients achieving high-quality glycemic control [time in range(TIR) > 70%, coefficient of variation (CV) < 36%, and no hypoglycemia].
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4243995706
02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In severely hyperglycemic overweight or obese patients with T2D during seven-day intensive therapy, degludec/liraglutide plus aspart showed higher time in range (84.03% versus 74.67%; P = 0.007) than glargine plus aspart.
In plain wordsIn overweight/obese patients with T2D, degludec/liraglutide plus aspart increased time in range versus glargine plus aspart.
Peptide
Liraglutide
Outcome
IncreaseTime in range
Study
n: not reported in source
Comparator
Insulin glargine plus insulin aspart
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Measurements
Time in range
84.03%
degludec/liraglutide plus aspart; P = 0.007
Time in range
74.67%
glargine plus aspart; P = 0.007
Source sentences
Summary
Compared with controls, the IDegLira group showed higher TIR (84.03% vs. 74.67%, P = 0.007) and lower time above range (TBR) (P = 0.005).
3 context sentences(design, population, supporting numbers)
Summary · context
To compare the efficacy of insulin degludec/liraglutide (IDegLira) versus insulin glargine, both combined with insulin aspart, for short-term intensive glycemic control in overweight or obese patients with type 2 diabetes mellitus (T2DM).
Summary · context
In this randomized study, severely hyperglycemic overweight or obese patients with T2DM received 7-day intensive therapy with either IDegLira plus insulin aspart or insulin glargine plus insulin aspart.
Summary · context
Secondary endpoints included continuous glucose monitoring (CGM)-derived metrics, insulin requirements, and insulin resistance and β-cell function indices.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4243995701
03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In severely hyperglycemic overweight or obese patients with T2D during seven-day intensive therapy, degludec/liraglutide plus aspart showed less time above range (P = 0.005) than glargine plus aspart.
In plain wordsIn overweight/obese patients with T2D, degludec/liraglutide plus aspart reduced time above range versus glargine plus aspart.
Peptide
Liraglutide
Outcome
DecreaseTime above range
Study
n: not reported in source
Comparator
Insulin glargine plus insulin aspart
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Compared with controls, the IDegLira group showed higher TIR (84.03% vs. 74.67%, P = 0.007) and lower time above range (TBR) (P = 0.005).
3 context sentences(design, population, supporting numbers)
Summary · context
To compare the efficacy of insulin degludec/liraglutide (IDegLira) versus insulin glargine, both combined with insulin aspart, for short-term intensive glycemic control in overweight or obese patients with type 2 diabetes mellitus (T2DM).
Summary · context
In this randomized study, severely hyperglycemic overweight or obese patients with T2DM received 7-day intensive therapy with either IDegLira plus insulin aspart or insulin glargine plus insulin aspart.
Summary · context
Secondary endpoints included continuous glucose monitoring (CGM)-derived metrics, insulin requirements, and insulin resistance and β-cell function indices.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4243995702
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In severely hyperglycemic overweight or obese patients with T2D during seven-day intensive therapy, degludec/liraglutide plus aspart showed lower mean glucose (8.26 versus 9.74 mmol/L; P <= 0.003) than glargine plus aspart.
In plain wordsIn overweight/obese patients with T2D, degludec/liraglutide plus aspart lowered mean glucose versus glargine plus aspart.
Peptide
Liraglutide
Outcome
DecreaseMean glucose
Study
n: not reported in source
Comparator
Insulin glargine plus insulin aspart
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Measurements
Mean glucose
8.26 mmol/L
degludec/liraglutide plus aspart; P <= 0.003
Mean glucose
9.74 mmol/L
glargine plus aspart; P <= 0.003
Source sentences
Summary
Glycemic variability indices, including mean glucose(MG) (8.26 vs. 9.74 mmol/L), were significantly improved (all P ≤ 0.003).
3 context sentences(design, population, supporting numbers)
Summary · context
To compare the efficacy of insulin degludec/liraglutide (IDegLira) versus insulin glargine, both combined with insulin aspart, for short-term intensive glycemic control in overweight or obese patients with type 2 diabetes mellitus (T2DM).
Summary · context
In this randomized study, severely hyperglycemic overweight or obese patients with T2DM received 7-day intensive therapy with either IDegLira plus insulin aspart or insulin glargine plus insulin aspart.
Summary · context
Secondary endpoints included continuous glucose monitoring (CGM)-derived metrics, insulin requirements, and insulin resistance and β-cell function indices.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4243995703
05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In severely hyperglycemic overweight or obese patients with T2D during seven-day intensive therapy, degludec/liraglutide plus aspart showed lower insulin requirements (37.95 versus 41.59 U/d; P = 0.03) than glargine plus aspart.
In plain wordsIn overweight/obese patients with T2D, degludec/liraglutide plus aspart reduced insulin requirements versus glargine plus aspart.
Peptide
Liraglutide
Outcome
DecreaseInsulin requirement
Study
n: not reported in source
Comparator
Insulin glargine plus insulin aspart
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Measurements
Insulin requirement
37.95 U/d
degludec/liraglutide plus aspart; P = 0.03
Insulin requirement
41.59 U/d
glargine plus aspart; P = 0.03
Source sentences
Summary
The IDegLira group required less insulin (37.95 vs. 41.59 U/d, P = 0.03), achieved glycemic targets faster (3.1 vs. 5.0 days, P < 0.001), and had a higher rate of high-quality glycemic control (65.1% vs. 36.5%, P = 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
To compare the efficacy of insulin degludec/liraglutide (IDegLira) versus insulin glargine, both combined with insulin aspart, for short-term intensive glycemic control in overweight or obese patients with type 2 diabetes mellitus (T2DM).
Summary · context
In this randomized study, severely hyperglycemic overweight or obese patients with T2DM received 7-day intensive therapy with either IDegLira plus insulin aspart or insulin glargine plus insulin aspart.
Summary · context
Secondary endpoints included continuous glucose monitoring (CGM)-derived metrics, insulin requirements, and insulin resistance and β-cell function indices.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4243995704
06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In severely hyperglycemic overweight or obese patients with T2D, short-term intensive therapy involving degludec/liraglutide plus aspart showed reduced insulin resistance (P <= 0.001); the specific comparison was unstated.
In plain wordsIn overweight/obese patients with T2D, intensive therapy involving degludec/liraglutide plus aspart reduced insulin resistance; its comparison was unstated.
Peptide
Liraglutide
Outcome
DecreaseInsulin resistance
Study
n: not reported in source
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Short-term reductions in insulin resistance and improvements in β-cell function indices were also observed (all P ≤ 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
To compare the efficacy of insulin degludec/liraglutide (IDegLira) versus insulin glargine, both combined with insulin aspart, for short-term intensive glycemic control in overweight or obese patients with type 2 diabetes mellitus (T2DM).
Summary · context
In this randomized study, severely hyperglycemic overweight or obese patients with T2DM received 7-day intensive therapy with either IDegLira plus insulin aspart or insulin glargine plus insulin aspart.
Summary · context
Secondary endpoints included continuous glucose monitoring (CGM)-derived metrics, insulin requirements, and insulin resistance and β-cell function indices.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4243995707
07HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In severely hyperglycemic overweight or obese patients with T2D, short-term intensive therapy involving degludec/liraglutide plus aspart showed improved beta-cell function indices (P <= 0.001); the specific comparison was unstated.
In plain wordsIn overweight/obese patients with T2D, intensive therapy involving degludec/liraglutide plus aspart improved beta-cell function; its comparison was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedBeta-cell function indices
Study
n: not reported in source
Analysis
Secondary
Outcome group
Glycemic control · Endocrine and hormones
Source sentences
Summary
Short-term reductions in insulin resistance and improvements in β-cell function indices were also observed (all P ≤ 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
To compare the efficacy of insulin degludec/liraglutide (IDegLira) versus insulin glargine, both combined with insulin aspart, for short-term intensive glycemic control in overweight or obese patients with type 2 diabetes mellitus (T2DM).
Summary · context
In this randomized study, severely hyperglycemic overweight or obese patients with T2DM received 7-day intensive therapy with either IDegLira plus insulin aspart or insulin glargine plus insulin aspart.
Summary · context
Secondary endpoints included continuous glucose monitoring (CGM)-derived metrics, insulin requirements, and insulin resistance and β-cell function indices.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4243995708
08HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In severely hyperglycemic overweight or obese patients with T2D during seven-day intensive therapy, glycemic variability indices improved with degludec/liraglutide plus aspart versus glargine plus aspart (P <= 0.003).
In plain wordsIn overweight/obese patients with T2D, degludec/liraglutide plus aspart improved glycemic variability versus glargine plus aspart.
Peptide
Liraglutide
Outcome
Direction not reportedGlycemic variability indices
Study
n: not reported in source
Comparator
Insulin glargine plus insulin aspart
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Glycemic variability indices, including mean glucose(MG) (8.26 vs. 9.74 mmol/L), were significantly improved (all P ≤ 0.003).
3 context sentences(design, population, supporting numbers)
Summary · context
To compare the efficacy of insulin degludec/liraglutide (IDegLira) versus insulin glargine, both combined with insulin aspart, for short-term intensive glycemic control in overweight or obese patients with type 2 diabetes mellitus (T2DM).
Summary · context
In this randomized study, severely hyperglycemic overweight or obese patients with T2DM received 7-day intensive therapy with either IDegLira plus insulin aspart or insulin glargine plus insulin aspart.
Summary · context
Secondary endpoints included continuous glucose monitoring (CGM)-derived metrics, insulin requirements, and insulin resistance and β-cell function indices.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4243995709
09HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In severely hyperglycemic overweight or obese patients with T2D during seven-day intensive therapy, degludec/liraglutide plus aspart showed faster glycemic-target attainment (3.1 versus 5.0 days; P < 0.001) than glargine plus aspart.
In plain wordsIn overweight/obese patients with T2D, degludec/liraglutide plus aspart reached glycemic targets faster versus glargine plus aspart.
Peptide
Liraglutide
Outcome
DecreaseTime to glycemic target
Study
n: not reported in source
Comparator
Insulin glargine plus insulin aspart
Outcome group
Glycemic control · Metabolic and weight
Measurements
Time to glycemic target
3.1 days
degludec/liraglutide plus aspart; P < 0.001
Time to glycemic target
5 days
glargine plus aspart; P < 0.001
Source sentences
Summary
The IDegLira group required less insulin (37.95 vs. 41.59 U/d, P = 0.03), achieved glycemic targets faster (3.1 vs. 5.0 days, P < 0.001), and had a higher rate of high-quality glycemic control (65.1% vs. 36.5%, P = 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
To compare the efficacy of insulin degludec/liraglutide (IDegLira) versus insulin glargine, both combined with insulin aspart, for short-term intensive glycemic control in overweight or obese patients with type 2 diabetes mellitus (T2DM).
Summary · context
In this randomized study, severely hyperglycemic overweight or obese patients with T2DM received 7-day intensive therapy with either IDegLira plus insulin aspart or insulin glargine plus insulin aspart.
Summary · context
Secondary endpoints included continuous glucose monitoring (CGM)-derived metrics, insulin requirements, and insulin resistance and β-cell function indices.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4243995705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Comparative analysis of IDegLira versus insulin glargine in short-term intensive therapy for overweight or obese patients with type 2 diabetes mellitus.

Summary

Results from this study9

Studies that did not test the peptide alone9

Version history

Subjects

Publication types

MeSH terms

Keywords